JoelSchlessingerMDFAAD, FAACS, FAAP

Dermatology • Omaha, NE

Acne & Rosacea, Cosmetic Dermatology, Dermatologic Surgery

Skin Specialists PC/LovelySkin

Join to view full profile

Dr. Schlessinger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schlessinger's full profile

Already have an account?

Office
2802 Oak View Dr
Omaha, NE 68144
Phone+1 402-334-7546

Fax+1 402-334-8627

Summary

I am a board-certified dermatologist, cosmetic surgeon and pediatrician as well as the CEO of LovelySkin.com, the 12th largest online seller of cosmetics based on Internet Retailer data.
Professional distinctions include being one of six founders of the American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS), past president of ASCDAS, past president of the Nebraska Dermatology Society and author of multiple articles in reference dermatology literature.
In addition, my clinic has an active research department, having performed over 250 clinical trials since 1993, ranging from neurotoxin trials to filler trials as well as psoriasis, acne, eczema and device trials.
Along with my son, Daniel Schlessinger MD, I developed FixMySkin 1% Hydrocortisone Balm, a patented stick which contains 1% hydrocortisone. This has been covered by the New York Times, Allure. It has sold over 250,000 units.

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Dermatology, 1989 - 1992
University of Alabama, Children’s Hospital of AlabamaResidency, Board Certified, 1986 - 1988
University of Alabama Medical CenterResidency, Pediatrics, 1985 - 1988
University of Alabama, Children’s Hospital of AlabamaInternship, 1985 - 1986
Baylor College of MedicineClass of 1985, MD
Brown University Medical SchoolBasic Sciences, Med School, 1981 - 1983
University of Rhode IslandB.A, Biology, Summa Cum Laude, 1980

Certifications & Licensure

HI State Medical License 2009 - 2026
NE State Medical License 1992 - 2026
TN State Medical License 1986 - 2026
NV State Medical License 2014 - 2025
IA State Medical License 1992 - 2006
TX State Medical License 1986 - 1992
AL State Medical License 1986 - 1991
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Best in Omaha in Cosmetic Surgery Omaha Magazine, 2000-2023
Regional Top Doctor Castle Connolly, 2023
Marquis Who’s Who in America 2006-2015, 2015
Best Doctors in America 2011-2015
Elle ‘Genius’ Selection 2011
Winner, Best Dermatologist in Omaha Readers Choice/WOWT Awards/Omaha Magazine
Selected one of American’s Top Physicians, Dermatology
Fellow (FAAD) American Academy of Dermatology
Fellow (FASDS) American Society for Dermatologic Surgery
Join now to see all

Clinical Trials

Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Start of enrollment: 2006 Dec 01
Completed
Phase 3
Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens Start of enrollment: 2007 Mar 01
Completed
Phase 4
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines Start of enrollment: 2007 Jun 18
Completed
Phase 3
Phase 2 Study for the Treatment of Superficial Lipomas Start of enrollment: 2007 Nov 01
Completed
Phase 2
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines Start of enrollment: 2008 Oct 01
Completed
Phase 3
Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study Start of enrollment: 2009 Dec 01
Completed
Phase 2
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Start of enrollment: 2010 Apr 01
Completed
Phase 2
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults Start of enrollment: 2010 May 01
Completed
Phase 2
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 Mar 01
Completed
Phase 3
A Study to Assess Injection Comfort of Two Formulations of ATX-101
Completed
Phase 1
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Start of enrollment: 2011 Jun 01
Completed
Phase 3
An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects Start of enrollment: 2014 Jan 01
Completed
Phase 2
Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea Start of enrollment: 2014 May 01
Completed
Not Applicable
Mirvaso in Use Study Start of enrollment: 2014 Sep 01
Completed
Phase 4
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 Start of enrollment: 2015 May 01
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat Start of enrollment: 2016 Dec 22
Completed
Phase 2
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Feb 20
Completed
Phase 3
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI) Start of enrollment: 2020 Jun 29
Active, not recruiting
Phase 2
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Start of enrollment: 2021 Sep 20
Completed
Phase 2
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period Start of enrollment: 2023 Nov 06
Recruiting
Phase 3
Roles: Principal Investigator
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Start of enrollment: 2023 Oct 23
Recruiting
Phase 2
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata Start of enrollment: 2023 Feb 27
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

20 citations
Short-term Combination Therapy and Long-Term Relapse Prevention in the Treatment of Severe Acne Vulgaris
Jerry Tan, Stein Gold L, Schlessinger J, Robert T. Brodell, Jones T
Journal of Drugs in Dermatology. 2012-02-01
300 citations
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Parallel Randomized Trial
Alexa B. Kimball, Francisco A. Kerdel, David Adams, Ulrich Mrowietz, Joel M. Gelfand
Annals of Internal Medicine. 2012-12-18
52 citations
A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne.
Linda Stein Gold, Jerry Tan, Alma Cruz-Santana, Kim A. Papp, Yves Poulin
Cutis. 2009-08-01

Lectures

Cosmetic Surgery Forum - Discussions in Dermatology
Cosmetic Surgery Forum, Las Vegas, Nevada - 11/29/2012

Press Mentions

10 Ingredients That Can Help Fight Signs of Premature Skin AgingSeptember 24th, 2021
Which Probiotic for Which Disease? Part 1August 7th, 2021
Rinvoq Has Quicker Onset, Higher EASI Scores Than Dupixent in Phase 3b Study of Adults with Atopic DermatitisAugust 4th, 2021
Join now to see all

Committees

member, ASDS Membership Workgroup Committee 2010 - 2014

Research History

Advanced Skin Research CenterDirector of the Advanced Skin Research Center, Omaha, Nebraska. Have conducted over 250 clinical trials including botulinum toxin, fillers, psoriasis, acne, skin cancer and eczema trials.1994 - Present